[go: up one dir, main page]

CH671157A5 - Stabiles pharmazeutisches praeparat, enthaltend granulocytkolonie stimulierender faktor, und verfahren zur herstellung desselben. - Google Patents

Stabiles pharmazeutisches praeparat, enthaltend granulocytkolonie stimulierender faktor, und verfahren zur herstellung desselben. Download PDF

Info

Publication number
CH671157A5
CH671157A5 CH2727/87A CH272787A CH671157A5 CH 671157 A5 CH671157 A5 CH 671157A5 CH 2727/87 A CH2727/87 A CH 2727/87A CH 272787 A CH272787 A CH 272787A CH 671157 A5 CH671157 A5 CH 671157A5
Authority
CH
Switzerland
Prior art keywords
acid
pharmaceutical preparation
molecular weight
polyoxyethylene
csf
Prior art date
Application number
CH2727/87A
Other languages
German (de)
English (en)
Inventor
Minoru Machida
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of CH671157A5 publication Critical patent/CH671157A5/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CH2727/87A 1986-07-18 1987-07-16 Stabiles pharmazeutisches praeparat, enthaltend granulocytkolonie stimulierender faktor, und verfahren zur herstellung desselben. CH671157A5 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP16948686 1986-07-18
JP16948886 1986-07-18
JP16948786 1986-07-18
JP16948986 1986-07-18

Publications (1)

Publication Number Publication Date
CH671157A5 true CH671157A5 (de) 1989-08-15

Family

ID=27474266

Family Applications (1)

Application Number Title Priority Date Filing Date
CH2727/87A CH671157A5 (de) 1986-07-18 1987-07-16 Stabiles pharmazeutisches praeparat, enthaltend granulocytkolonie stimulierender faktor, und verfahren zur herstellung desselben.

Country Status (24)

Country Link
KR (1) KR930004597B1 (sh)
CN (1) CN1033738C (sh)
AT (1) AT402259B (sh)
AU (1) AU611856B2 (sh)
BE (1) BE1000253A3 (sh)
CA (1) CA1297007C (sh)
CH (1) CH671157A5 (sh)
DE (1) DE3723781C2 (sh)
DK (1) DK171308B1 (sh)
ES (1) ES2010226A6 (sh)
FR (1) FR2601591B1 (sh)
GB (1) GB2193631B (sh)
GR (1) GR871067B (sh)
HK (1) HK64893A (sh)
HU (1) HU198627B (sh)
IE (1) IE60290B1 (sh)
IL (1) IL83220A (sh)
IT (1) IT1218927B (sh)
NL (1) NL192917C (sh)
NO (1) NO171828C (sh)
PT (1) PT85343B (sh)
SE (1) SE503312C2 (sh)
SG (1) SG64393G (sh)
YU (1) YU47543B (sh)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929442A (en) * 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
NO179479C (no) * 1988-03-11 1996-10-16 Teikoku Seiyaku Kk Fremgangsmåte for fremstilling av et intravaginalt farmasöytisk preparat
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US5349052A (en) * 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
GB8824591D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
US6132763A (en) * 1988-10-20 2000-10-17 Polymasc Pharmaceuticals Plc Liposomes
US5104651A (en) * 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
EP0459516A1 (en) * 1990-06-01 1991-12-04 Kirin-Amgen, Inc. Oral dosage form of biologically active proteins
JP3249147B2 (ja) * 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2686900B1 (fr) * 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
FR2693907B1 (fr) * 1992-07-23 1994-09-02 Rhone Poulenc Rorer Sa Procédé d'administration de solutions de facteur de stimulation des colonies granulocytaires.
EP0582932A1 (de) * 1992-08-11 1994-02-16 F. Hoffmann-La Roche Ag Therapeutisches System zur parenteralen Verabreichung von hämatopoetischen Wachstumsfaktoren
DE4242863A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
DE4242919A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Verfahren zur Herstellung von lagerstabilen wässrigen pharmazeutischen Zubereitungen von G-CSF
US20030053982A1 (en) 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
AU695129B2 (en) * 1995-02-06 1998-08-06 Genetics Institute, Llc Formulations for IL-12
TW434020B (en) * 1995-03-15 2001-05-16 Kirin Brewery Methods for preventing adsorption of thrombopoietin (TPO), and stable top-containing compositions
TW434021B (en) * 1995-03-15 2001-05-16 Kirin Brewery Methods for preventing adsorption of thrombopoietin (TPO), and stable TPO-containing compositions
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
EP1060746A4 (en) * 1998-03-06 2002-06-19 Chugai Pharmaceutical Co Ltd PROTEIN-FREE PREPARATIONS
US6979442B1 (en) * 1998-08-17 2005-12-27 Pfizer Inc. Stabilized protein compositions
WO2001017542A1 (fr) * 1999-09-08 2001-03-15 Chugai Seiyaku Kabushiki Kaisha Preparation de solution de proteines et procede de stabilisation associe
TR200401573T4 (tr) * 2000-02-29 2004-08-23 Pfizer Products Inc. Stabilize edilmiş granülosit koloni uyarıcı faktör
WO2001064241A1 (fr) * 2000-02-29 2001-09-07 Chugai Seiyaku Kabushiki Kaisha Preparations stabilisees a long terme
CA2747325A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
CA2420850A1 (en) 2000-09-01 2003-02-28 Chugai Seiyaku Kabushiki Kaisha Solution formulations having long-term stability
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
CA2471363C (en) 2001-12-21 2014-02-11 Human Genome Sciences, Inc. Albumin fusion proteins
US7423007B2 (en) 2002-08-27 2008-09-09 Biokine Therapeutics Ltd. Cxcr4 antagonist and use thereof
EP1598074B1 (en) 2003-02-28 2019-01-02 Chugai Seiyaku Kabushiki Kaisha Stabilized protein-containing formulations
DE202006020194U1 (de) 2006-03-01 2007-12-06 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung
EP2104507A4 (en) 2006-12-21 2011-05-25 Biokine Therapeutics Ltd T-140 PEPTIDE ANALOGUE WITH CXCR4 SUPERAGONIST ACTIVITY FOR CANCER THERAPY
WO2010092571A2 (en) 2009-02-11 2010-08-19 Yeda Research And Development Co. Ltd. Short beta-defensin-derived peptides
CN102740840A (zh) * 2010-01-19 2012-10-17 韩美科学株式会社 长效g-csf缀合物的液体制剂
EP2399572A1 (en) 2010-06-22 2011-12-28 Sandoz AG Long-term storage of non-glycosylated recombinant human G-CSF
EP3943098A3 (en) 2015-07-16 2022-05-11 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
BR112018016924A2 (pt) 2016-02-23 2019-01-02 Biokine Therapeutics Ltd método de seleção de regime de tratamento para indivíduo que tem leucemia mieloide aguda (lma), método de maximização de resposta ao tratamento de leucemia mieloide aguda (lma), método de tratamento de lma, antagonista de cxcr4 e agente quimioterápico no tratamento de lma
WO2018138267A1 (en) 2017-01-27 2018-08-02 Cinfa Biotech S.L. Method for determining the efficacy of a g-csf containing composition
PL3797752T3 (pl) * 2018-05-21 2024-10-28 Chugai Seiyaku Kabushiki Kaisha Preparat liofilizowany szczelnie zamknięty w pojemniku szklanym

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652636A1 (de) * 1976-11-19 1978-05-24 Hans Uwe Dr Rer Nat Wolf Verfahren zur stabilisierung von proteinen und verwandten verbindungen waehrend ihrer reinigung, isolierung und lagerung
SE451844B (sv) * 1978-03-20 1987-11-02 Morinaga Milk Industry Co Ltd Glykoprotein, forfarande for framstellning derav samt terapeutiskt medel innehallande nemnda glykoprotein
DE3380726D1 (en) * 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
JPS60228422A (ja) * 1984-04-26 1985-11-13 Suntory Ltd 安定化された生理活性物質製剤
JPS61227526A (ja) * 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
JPS6191131A (ja) * 1984-10-09 1986-05-09 Chugai Pharmaceut Co Ltd 医薬品の吸着防止方法および組成物
ATE80894T1 (de) * 1985-02-05 1992-10-15 Cetus Oncology Corp Reinigung des natuerlichen kolonie-stimulierenden faktors-1.
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPH0618778B2 (ja) * 1985-10-04 1994-03-16 中外製薬株式会社 白血球減少症治療剤

Also Published As

Publication number Publication date
YU47543B (sh) 1995-10-03
FR2601591A1 (fr) 1988-01-22
SE503312C2 (sv) 1996-05-13
FR2601591B1 (fr) 1991-04-26
DK171308B1 (da) 1996-09-02
IL83220A0 (en) 1987-12-31
KR930004597B1 (ko) 1993-06-01
CA1297007C (en) 1992-03-10
IE60290B1 (en) 1994-06-29
NL8701640A (nl) 1988-02-16
IT8767594A0 (it) 1987-07-10
PT85343B (pt) 1990-04-30
NO872966D0 (no) 1987-07-16
ES2010226A6 (es) 1989-11-01
HK64893A (en) 1993-07-16
YU134287A (en) 1989-06-30
NL192917C (nl) 1998-05-07
AU611856B2 (en) 1991-06-27
GR871067B (en) 1987-11-19
BE1000253A3 (fr) 1988-09-27
DK368387D0 (da) 1987-07-15
HU198627B (en) 1989-11-28
AU7566587A (en) 1988-01-21
NL192917B (nl) 1998-01-05
AT402259B (de) 1997-03-25
IE871933L (en) 1988-01-18
GB2193631A (en) 1988-02-17
GB8716904D0 (en) 1987-08-26
ATA177587A (de) 1996-08-15
DE3723781A1 (de) 1988-01-21
DK368387A (da) 1988-01-19
KR880001297A (ko) 1988-04-22
NO872966L (no) 1988-01-19
CN87104963A (zh) 1988-02-24
DE3723781C2 (de) 1999-09-02
NO171828B (no) 1993-02-01
SE8702907D0 (sv) 1987-07-17
IT1218927B (it) 1990-04-24
HUT44941A (en) 1988-05-30
IL83220A (en) 1993-01-31
SE8702907L (sv) 1988-01-19
SG64393G (en) 1993-08-06
PT85343A (en) 1987-08-01
GB2193631B (en) 1990-11-21
CN1033738C (zh) 1997-01-08
NO171828C (no) 1993-05-12

Similar Documents

Publication Publication Date Title
CH671157A5 (de) Stabiles pharmazeutisches praeparat, enthaltend granulocytkolonie stimulierender faktor, und verfahren zur herstellung desselben.
DE69311278T2 (de) Stabile pharmazeutische Zubereitung mit Fumagillolderivaten
DE3520228C2 (de) Wasserlösliche bioaktive Trockenfeststoffzusammensetzung, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Präparate
DE69020573T3 (de) Verfahren zur wachstumshemmung von stammzellen.
DE69005394T2 (de) Zusammensetzungen welche komplexe von hyaluronsäure enthalten und verfahren zu deren herstellung.
DE69002795T2 (de) Stabilisierte, den epidermalen Wachstumsfaktor enthaltende Mittel.
DE69327582T2 (de) Methoden zur Behandlung von Interleukin- 1 und - Tumor - Nekrose - Faktor - verursachten Krankheiten
CA1209473A (en) Stable interferon b-composition and a method of stabilizing interferon b
WO2007099145A1 (de) G-csf-flüssigformulierung
EP0392429A1 (de) Psoralen-Reagens
EP1206244B1 (de) Wässrige arzneimittelformulierung von moxifloxacin oder salzen davon
DE60103940T2 (de) Stabilisierter Granulozyten-Kolonie-stimulierender Faktor
DE69101784T2 (de) Stabilisierte zusammensetzung enthaltend ein fibroblastwachstumsfaktor.
DE3740588C2 (de) Temperaturstabiles Breitband-Antibiotikum
RU2025120C1 (ru) Способ получения препарата, содержащего фактор /g-csf/, стимулирующий рост колоний гранулоцитов
DE69622854T2 (de) Arzneimittel zur Heilung von Thrombozytopenie
EP0655249A1 (de) Moenomycin als Arzneimittel zur Behandlung von Magengeschwüren
DK153123B (da) Fremgangsmaade til fremstilling af et pulverformigt farmaceutisk praeparat indeholdende amoxycillin-trihydrat
DE69936527T2 (de) Verwendung von modifiziertem lysozyme c in der herstellung von pharmazeutika zur krankheitsbehandlung
EP0420049A1 (de) Stabilisierte Leukocyten-Interferone
DE69209486T2 (de) Stabilisierte pharmaceutische Zusammensetzung die nicht-glycozylierte, reduzierte rekombinante human IL-2 umfasst und Verfahren zu ihrer Herstellung
EP0456153B1 (de) Galenische wässrige Formulierungen von Erythropoietin und ihre Verwendung
EP0458949B1 (de) Stabilisierung von k1k2p pro
DE69118796T2 (de) Vernarbungsfördernde pharmazeutische Verbindung
DE19957371A1 (de) Mitomycin C-Lösung

Legal Events

Date Code Title Description
PL Patent ceased